Chikwawa annual project technical report submitted to Technical Consultative Committee (TCC)

I t,.t I t RESERVED FOR PROJECT LOGO/HEADING ORIGINAL: English COUNTRYAIOTF: (I f;,fi,'o { Proiect Name: Ct\\ t(ut nw ft Approval year: Launching year Reporting Period: From To (Month/Year) ( Month/Year) Proiectyearofthisreport: (circleone) I 2 3 4 5 6 7 8 9 10 Date submitted: NGDO partner ANNUAL PROJECT TECHNICAL REPORT SUBMITTED TO TECHNICAL CONSULTATIVE COMMITTBE (TCC) DEADLINE FOR SUBMISSION: To APOC Management by 31 Januarv for March TCC meeting To APOC Management by 31 Julv for September TCC meeting AFRICAN PROGRAMME FOR ONCHOCERCTASTS CONTROL (APOC) VZ { ' ''' 4-'t' : .fo: Tcc J6 aL For lilfcri::'jirio,n To, .\ie P^tM V. B"kio"er Fix csb CoP 6rtE Bfu ,FD j ri rilrrr Z00l WHO/APOC, 24 November 2004 ( ? t1, ANNUAL PROJECT TECHNICAL RBPORT TO TECHNICAL CONSULTATIVE COMMITTEE (TCC) ENDORSEMENT Please confirm you have read this report by signing in the appropriate space. OFFICERS to sign the report: Country: MALAWI. National Coordinator Name MK A S aturelgn ,11 I ,l Date: Zonal Oncho Coordinator Name: CORNELIUS MUHAMA Signature: li....i.].i.!\ !^ti vvr-('i Date: l,'o I LlI DHO Representative Name: Dr M MBEWE S i gnature :i t, \rv ileK,r-*s Date This report has been prepared by Name : CORNELIUS MUHAMA. Designation Signature : ...... Date ll WHO/APOC. 24 November 2004 I I ,.,-+ t I ?" Table of contents DEFINITIONS......... 2.7. ORDERTNG, sroRAGE AND DELTvERy oF IVERMECTIN................ 2.8. CouuuNrry sELF-MoNrroRtNG RNo SrarsHoLDERS MpeuNc2.9. SuppnvrsroN............... 2.9.L Provide aflow chart of supervisionhierarchy. 2.9.2. What were the main issues identified during superttision? 2.9.3. L[/as a supervision checklist used? ......... V VI FOLLOW UP ON TCC RECOMMENDATIONS EXECUTIVE SUMMARY SECTION 1 : BACKGROUND INFORMATION........ l.l. GsNpRal rNFoRMATroN................ 1 .l .1 Description of the project (briefly) 1.1.2. Partnership 1.2. PopulauoN SECTION 2: IMPLEMENTATION OF CDTI................. 2.1. TrrvelrNp oF ACTrvtnES .............. ......................52.2. Anvocacy ....................72.3. Moslt-tzartoN, SENSITIZATIoN AND HEAL'rH EDUCATIoN oF AT RrsK coirauuNrrrEs..T2.4. CovvuNrry rNVoLVEMENT............ ...................82.5. CRpacrry BUTLDTNG ..........,...,.........92.6. TnpnrnapNrs................ .................1I 2.6.1. Treatment figlres ........... ...... I I2.6.2 What are the causes of absenteeism?............. .. . ... ..132.6.3 What are the reasons for refusals? ................ ............ 132.6.1 Briefly describe all known and verified serious adverse events (SAEs) that.... I3 2.6.5. Trend of treatruent achievement from CDTI project inception to the current year l5 I 2 3 3 J 3 4 5 t6 l6 t7 17 I7 l7 2 9.4 2.9.5, 2.9 6 what were the outcomes at each level of CDTI implementation supervision? l7 llas feedback given to the person or groups supervised? ............. 17 Hov, v,as the feedback used lo improve the overall performance of the project? l7 SECTION 3: SUPPORT TO CDTI l7 3.1. EeurpH,tsNr 3.2. FrNRNcrnl coNTRrBUt'roNS oF THE pAR-TNERS AND coMMUNITIES.......3.3. OrHen FoRMS oF'coMMUNIly suppoRT 3.4. ExppNotluRE pER ACTrvn-y ........,... SECTION 4: SUSTAINABILITY OF CDTI.. 4.1. INIERNaT-; TNDEpENDHNl pARTtctpAToRy MoNrroRrNG; EvRluartoN ...................20 1.1.1 Was Monitoring/evaluation carried out during the reporting period? (tick any of theJollotuingwhich are applicable). ........20 1.1.2. lYhat were the recommendations'? .. . ....20 4.1.3. How have they been implemented?.............. ..............20 17 t9 t9 .................. I 9 ..................20 llr WHO/APOC, 24 November 2004 4.2. SusrRINaetLITy oF pRoJEC'ts: eLAN AND sET TARGETS (uaNoaroRy AT ...............21 Yn 3)......... ...........21 1.2.1. Planning at all relevant levels ................21 1.2.2. Funds ......21 4.2.3 Transport (replacentent and maintenance) ................21 1.2.1. Other resources... ..................21 4.2.5. To what extent has the plan been implemented............... .............21 4.3. INlecRarroN ............... ..,,.............21 1.3.1. Iyermectin delivery mechanisms ..............21 1.3.2. Training .............. 21 1.3.3. Joint supervision and monitoringwith otherprograms..................................21 1.3.4. Release offundsfor project activities ......21 1.3.5. Is CDTI included in the PHC budget? .......................21 1.3.6. Describe other health programnxes that are using the CDTI structure and hov' this was achieved. What have been the achieyements? ............. ..................21 1.3.7. Describe others issues considered in the integration of CDTL.............. .... ..21 4.4. OpsnarroNAl RESEARCH.. ..................21 4.4. l. Stmtmarize in not more than one half of a page the operational research undertaken in the project area within the reporting period. . . . .. .. .... . ............ . 2 I 1.4.2. How were the results applied in the projectT ............. ..................21 SECTION 5: STRENGTHS, WEAKNESSES, CHALLENGES, AND OPPORTUNITIES.... 22 SECTION 6: UNIQUE FEATURES OF THE PROJECT/OTHER MATTERS 22 lv WHO/APOC. 24 November 2004 Acronyms APOC ATO ATrO CBO CDD CDTI CSM LGA MOH NGDO NGO NOTF PHC REMO SAE SHM TCC TOT UNICEF UTG wHo African Programme for Onchocerciasis Control Annual Treatment Objective Annual Training Objective Commun ity-Based Organ ization Commun ity-Directed Distributor Community-Directed Treatment with lvermectin Community Self-Monitoring Local Government Area Ministry of Health Non-Governmental Development Organization Non-Governmental Organization National Onchocerciasis Task Force Primary health care Rapid Epidemiological Mapping of Onchocerciasis Severe adverse event Stakeholders meeting Technical Consultative Committee (APOC scientific advisory group) Trainer of trainers United Nations Children's Fund Ultimate Treatment Goal World Health Organization WHO/APOC. 24 November 2004 Definitions (i) Total population: the total population living in meso/hyper-endemic communities within the project area (based on REMO and census taking). (ii) Elieible population: calculated as 84%o of the total population in meso/hyper- endemic communities in the project area. (iii) Annual Treatment Objective: (ATO): the estimated number of persons living in meso/hyper-endemic areas that a CDTI project intends to treat with ivermectin in a given year. (iv) Ultimate Treatment Goal (UTG): calculated as the maximum number of people to be treated annually in meso/hyper endemic areas within the project area, ultimately to be reached when the project has reached full geographic coverage (normally the project should be expected to reach the UTG at the end of the 3'd year ofthe project). (v) Therapeutic coverage: number of people treated in a given year over the total population (this should be expressed as a percentage). (vi) Geographical coverage: number of communities treated in a given year over the total number of meso/hyper-endemic communities as identified by REMO in the project area (this should be expressed as a percentage). (vii) Integration: delivering additional health interventions (i.e. vitamin A supplements, albendazole for LF, screening for cataract, etc.) through CDTI (using the same systems, training, supervision and personnel) in order to maximise cost- effectiveness and empower communities to solve more of their health problems. This does not include activities or interventions carried out bv communitv distributors outside of CDTI. (viii) Sustainability: CDTI activities in an area are sustainable when they continue to function effectively for the foreseeable future, with high treatment coverage, integrated into the available healthcare service, with strong community ownership, using resources mobilised by the community and the government. (ix) Community self-monitoring (CSM): The process by which the community is empowered to oversee and monitor the performance of CDTI (or any community- based health intervention programme), with a view to ensuring that the programme is being executed in the way intended. It encourages the community to take full responsibility of ivermectin distribution and make appropriate modifications when necessary. vl WHO/APOC. 24 November 2004 FOLLOW UP ON TGC REGOMMENDATIONS Using the table below, fill in the recommendations of the last TCC on the project and describe how they have been addressed. TCC session (Please add more rows if necessary) Number of Recommendation in the Report TCC RECOMMENDATIONS ACTIONS TAKEN BY THE PROJECT FOR TCC/APOC MGT USE ONLY WHO/APOC. 24 November 2004 Executive Summary Prepare un Executive summary of tlte report in not more than one page, l. Background on treatment and population data - Total communities, communities treated, total population, UTG, ATO and persons treated. 2. Background on population movements. 3. Training data - CDDS, health workers, Total population (community) per CDD trained 4. Challenges and how they were overcome. 2 WHO/APOC. 24 November 2004 SEGTION t: Background information 1.1. General information l.l.l Description of the project (briefly) Geographical location, topography, climate Population: activities, cultures, language Communication systems (roads. . .) Adm inistration structure Health system & health care delivery (provide the number of health posts/centers in the project area if the information is available). Number of health staff in project area and number of health staff involved in CDTI activities. Table 1: Number of health staff involved in CDTI (Please add more rows if necessary) District/LGA Number of hellth staff involved in CDTI activities. Total Number of health staff in the entire project area Number of health staff involved in CDTI B2 Percentage Br=Brl B, *100 CHIKWAWA 79 6t 77.J I I I Total 1.1.2. Partnership Indicate the partners involved in project implementation at all levels [MoH, NGDOs(national/international), communities, local organizations, etc.] Describe overall working relationship among partners, clearly indicating specific areas of project activities (planning, supervision, advocacy, planning, mobilization, etc) where all partners are involve State plans, if any, to mobilize the state/region/district/LGA decision-makers, NGDOs, NGOs, CBOs, to assist in CDTI implementation. 3 WHO/APOC. 24 November 2004 B, $ 6l Lo Eo o z s o.l(, o o (.) Lr 0) C) o a(H i. q)L o o 'd L C) o o 0) o (! () 0.) (H o a t- ,o L(.) o () !(.) a do c'd c)() 'a L o- C) (.) o. o (! q L C) o Cf) F aibo o E E o C) (.) P ao (.) (E 0.) (.) bo(n l- E E o O L o C) bo c/) oL(! o >.(ts L(n(-) \J$ o'\ a. U U a\$ u q)\ -o >' B s Lc uq) o'\ a_ a) S t a)\ 5\6 $ \ B U s a) o $s ,a" o'\s -o s \ U sU il()t\5 iUq) o'\\ \ \)\ \) U E o L o a- 50 L o o- oL O bo L o o E 0) (.) L ()L f0 o L(.) (.) c) CI Iq) 0) o() .V a o o- o o- E .f -; o 0) a () oL a L() o o o -O^d! 0r l-.1 -o\JG C) (d(! o2 =ovo(.) -Q(! a=9z .^ c) .-u L =a Z p o' U p r\ :@i c.t aJ- k6J 3oo \-L So *g) .Yo 3oo r\ -= so)iaSo &,6v()!'= >Loo- .. c) ! \LSA\rY5.O-a ooq .so\ (.) u(g P' 4: A\ qJ I\ o -N q) % S C3O'5 flEr!= IEc=O(:E:. c'rl .olNEIrdlFFI D = uv o'\otr) \o @ o\ oo ...lt-- o. oo aa c! .= o.N; -?.gEE E t (,E o!! L'=eG9Ftr- *v.-u1 >,! o o * 'J-, i E 9' N: 'EgE ;!c gsi + il o\ co $ oo a.l CO F- ah 0) o! ahq) CJ ol €l .Yq E9o: tr o :''l(1 E E >o+E N ;.(!q.=in ?oU 8SEE* +_ il IL o3o ON o,: cEO F tr) tr) 6ttr9oEr= i- L !t d!: 6 = q/.: E *q.r 9' -v9FLrA-^ t-- oo\o co o. ti q, q) .=E ar EcEe dor*l;< E c! a,l F BV Tr Q -l - F t. ASEGTION 2: Implementation of GDTI 2.1. Timeline of activities Fill in table 3, timeline of activities for areas treated in current year, indicating when the key activities were implemented by the month they began and the month they ended. 5 ACTI\'ITY STARTING MONTH ENDING MONTH PLANNING MEETING WITH HSAs AUGUST SEPTEMBER PLANNING meeting WITH CDDs AUGUST SEPTEMBER INITIAL TRAINING FOR HSAs AUGUST SEPTEMBER INITIAL TRAINING FOR CDDs AUGUST SEPTEMBER DRAMA GROUP TRAINING SEPTEMBER SEPTEMBER DRAMA SHOWS SEPTEMBER OCTOBER MECTIZAN DISTRIBUTION SEPTEMBER NOVEMBER COMMUNITY MOBILISATION JUNE OCTOBER WHO/APOC. 24 November 2004 s O c.l o E 0) o z <fN U o .| \o o o E OU I ?4UU AJ q: \ q) L 't q) % o* ! () (.) LL (.) o 0) C)L oL o r (.) o (! q) () E F ..;1 0Jl _l -ol(gI r-l U) q) O o! EE o(, L! co r! o z a0trE ?tr .J o. O OI o EE(, & rl] a -F() u0FE Fa I C) p o 0) q) U o9 *o trE () a0EE J a OI 3 EOEE (,) tJ]F u)&ALN aoCt Faf o = c!=Nr Er9a trE () frl a F(, c a0rE liE t! z) F] o q) Yf() -l F 3 2.2. Advocacy State the number of policy/decision makers mobilized at each relevant level during the current year; the reason(s) for undertaking the advocacy and the outcome. Describe difficulties/constraints being faced and suggestions on how to improve advocacy. 2.3. Mobilization, sensitization and health education of at risk communities Provide information on The use of media and/or other local systems to disseminate information Mobilization and health education of communities including women and minorities Response of target commun ities/villages Accomplishments Suggest ways to improve mobilization and sensitization of the target communities. 7 WHO/APOC. 24 November 2004 c.) c.l 0) ,o E 6) z !f, c.l U o o. o d C) (c E (.) (! a oaa o .9 bo '6 -o a)L a C) a ,2 F Q 0) afl bo .E C) C) - .Ltbg aq() Ct=Lb0e E L!U .-t! F 0)^eox E-rnL0) =Pa9,.4 :o-co?,;:6 s-)Y-OUr EFE --A.dE'e0)-,o5-:i o sLu lvF_-L >'-() A E!9--- ^UL!- -Ur\P -v-q 9-5& bbL_ -E.9 a2 : E a:i f,v *P - r a a' O i 'vL:-JC9= X E o FC)'=l-P *-r^^L c):v - Yij at6.96- ->uE o eE;i!t-(,n5 > ='l 6E 9': CU +*^-@ !? -.--:.9 ;: a) = d rj;i - JHHXYSS .- U.- cioc+ilag 5oE 9.r'E -E9-d=!9<: i5-,! < o o C) Q ll * ";E0 a a[6 g Lq :.9 s T = E{ E E=i, Z?, aa =qtrc =o La trEO z= s el|r) F- + cq il ca ce F !rg6 > ::- (/ 2 U Z \o N oO )a .-L E9 e= ze ll * EO L Ec0 - >1 2 ? , =r.9a=P> -o E: l: Zec- ^.E.! -59GEc o tr= € N L .2 v l) ( F 4q!,U a) 4: L. p s -:g q) - a- F IJ U oI+-E=o.=Etr o'E o'5 trh o- fl() F.= J=CtrL!EEOrIC': $l . o..r Ir5l . 6JINFI oo 2.5. Gapacity building - Describe the adequacy of available knowledgeable manpower at all levels - Where frequent transfers of trained staff occur, state what the project is doing, or intends to do, to remedy the situation. (The most important issue to describe is what nxeasures were taken to ensure adequate CDTI implementation where not enough knowledgeable manpower v'us available or if staff are Jrequently transferred during the course of the campaign). During the campaign 8 staff members from three health facilities of the project got transferred out leaving only 4 staff members to cafter for the whole area. The project released a CDTI motorcycle to improve on transport so that a large area is reached. So far 3 staff members have been posted to the area and more expected to be posted there. 9 WHOiAPOC, 24 November 2003 N L 0) -o E o z $6l (, o I a t o { s o c o t \ p o \ o\ t s c o s\ g t - ,aill w :9- L! f .O U i. e! q F o q Q o z +\o .+ !f, t-. c.lN t o\ o q) o\ $ U + (, s: o<v Q Q il c e. LF 0 q,) .a'o' !sF o' oq) .6) Lcg ol- z al @ + 6l o\ q) o o\ cilVE E.;+0, F v r: cEL O-q\ - l- s- (,lrLt v 0t------- 9 ?i .: a} utr:--- 7 z--- arveli d' \o $ o o s ErQ Or'+F-d ! (, q = c,g q O -] 90) o) z a- a.l o s J I t-r F ?q aJ U \J 4t \ qJ o \Ja S 0) E(.) E F IJU q q) () (.) ! ,4);-r () co L(- .;1 (Jt -l.ot(dl FI F Table 6: Type of training underlaken (Tick the boxes where specific training was carried out during the reporting period) Any other comments 2.6. Treatments 2,6.1. Treatment figures If the project is not achieving 100% geographical coverage and a minimum of 650/o therapeutic coverage or the coverage rate is fluctuating, state the reasons and the plans being made to remedy this. Trainees Type of training CDDs Other Community members e.g Community supervisors Health Workers (frontline health faci Iities) MOH staff or Other Political Leaders Others(specify) Program management YES YES YES YES How to conduct Health education YES YES YES YES Management of SAEs YES CSM SHM Data collection YES YES YES Data analysis YES YES YES Report writing YES YES YES Others ( speci fy) ll WHO/APOC. 24 November 2003 +N o -o E O c z $N(, o a.] \)!o a g t3g \ 00 OO { \ B U S' :4. .:aia iU ooi ll 1EqJ 'a .t .s3FUU\s3 SS '!= i: s$ \isSF .S 'SrE Fg s'*!q su\ '=.1l\|! ]s' = ii 3 '!ut *Ftr ib .! Yrs bs * *JE !s{Y \:b C.Ea. s$ s' st d \u: gss E- .s sE oo uut 'Q\ * ET:s ov B. -{}t' :'J 3 *ss sE: ES \ trS :UB t.Ss 'Dir $a-I St u uts Srl- t\\'il ilE o QtL t\s\ bs L,/F (n oq(d !i C) 'd I o- 0,) '= .: d oL Q Eo o IL() o. oq 0) E () (n ^, c)vl L OI P -l o: "l: .91 o, Ul oLt o -l (J9l o =:Ouol c)ql !ol tr ol - -ol -l-l (d 5t i\zl; cd C)L cd O C) o- O o z tr.l -oE() 'r= C) .; (d a .9 E Oo .9 E() E OJ OIr^l & ,l 9 = sl uU dl .-6 ;''il --O'() tl ;^ - Pl vL ol !L-l L ^ ol(.): ol tr :1 q)l E; q'NE tsI,Y3 rl - - oJl :6t t96J trI =6 -t trF Zl< (!() (! ()(J H a. 0.) q() .: E E oo (.) EoOO -o5x .rEU9 o-d ot I 8Ol 6r o{ -l -Svl * = vl .- \dfl r^ a!l wu Ul .= .=Lt > UI ^lv! xt d xn- st J9olo- o rl o Lolo- () -ol -o zl? z all G)b{(Bl-o O o Eo ol(d Lb{ o()l b4 (! o (.) o Lo b{ a tr o o L .oI cgl EI trl LI €l ^:(.) \) v) \ \ -E AJa s I () L c! J o L a -o aql a (! o E (.,) LF r-l 0., I =l(6lFI 0) (.) o(d F q\ C) Cd () o0FU^S oo oF (.) (dr 0) bo Ho oo (!o 'a' -^\ cg oo o(.) () H() bo(n 0) oo(J^ P.\ () o.d L() EF a:o 9< or at6-th >.^ o::Ef = E =\ o€ o>oo o ! E z- .i: < =aAA bs EO zd a-\o 6 : o2- LE^-iD 9? o !lE tr! 6! o ! ct?q=2u E g o (t o. I! ld ! ooo 6 o F o\ c- (-- t-- ? so6:o E!o f o--z oo ooN(-- H =adaa 4as' FU N oo 9 'g E o 0d6s io 6 glE o F F- oo .o A a C) ooq = 6 .9 .= E E O Q ll * 9o i: uo\ ata - O E9 - U C Mq ==-Lzd a €N --aEbz EEgrjuE' F\J € c.l \Oa6-rd = q=;9 e!F^= +F-> - = - .c 9 AE E 8r,E E- _vcNYla e2a oaN '- \ErtihY o< Y :E F] 3 F a2.6.2 What are the causes of absenteeism? o Winter cropping. o No follow-up after a distribution. 2.6.3 What are the reasons for refusals? o Miscoceptions 2.6.4 Briefly describe all known and verified serious adverse events (SAEs) that occurred during the reporting period and provide (in table 8) the required information when available. In case the project did not have any cases of serious adverse events (SAE) during this reporting period, please tick in the box. No SAE case to report r3 WHO/APOC. 24 November 2004 N 0) -oF() z t a.l U o t \) \ q) Ir \.) -a q) v) c1 \,) Q qJ V): ;\ AJ\ t \) % e a* ! L() oo E o o- 0) C) bo LfE -o C)L! oo o -E IJ..J (n a C) o (.) aL(.) o .I o (F o C)(!(, #r crl =tFI o -E=o9:E2' iJ>"iC= L " oouil- I agUo aF) QOO o.9 C^ ooo o6_ qQ o-O^))\ o-q tr a6 ; E C.-6ooo A = ,L,E vos! H 6sci: c(! € - s, oo.N (u ! rY - :4rC;:ljg :E;5S> l I --r l l i-- I + _| I I I I It- laIElo to-lqt= lol- Gb:o!L A>.o-!6r6 FC =aN* HEZo>; bll o o o oIJ cd '/- a C,bo * a -t- I i ) I o 00 F oX ra () o\ co o\ oo o\ oo o\ oo o (! o ,-i r! td a ^o!U G^ - 06\ <'>J o\N 6i F- o\ o\ a oo oo 1l * - tri ki kl 5q o d^OL-o d Qo\ ooEAF o\ a.l \o ^\ o\ t-- o\ tr- t-r- l-l ,U s_a io =6z-i o. oo c.l o\ a-s t-- F.- oo o\ oo c.l r-. i! E6z 449' F9 N a\ 00$$ ooN co v t\ t-- \o N oo ao +8 d=..> a 3* o a- .+ o\t-- o\ oo e- .-. oo o o0 .._ () .= E E(, li -5 d' ^ qI)9lv- o 6\ o\ F- o\ oo o.l o\ ooN o\ € ct E+=i:=i::;ll*Yu 9ad*1 O .-) o\ a- \o o\ -o^\ r.l o50 o =:irq 5 ts3 E7aA { t'-. co c.l oo at @N --a 6o= ,ai' +F- ooN ooa\ €N caa.l bild =abi, E g * U€;I -e-I=!LUCs=nuc EO !i- F- oo c.l @ N ooN ooa.t tr- co o\ N N N c.l ol $ a.l o.l \o O c.l F- a.l ca N o{ N s c.l L() -o Eo o z .+ N (-, o .D cg I q) q) oo c) I 3p q) q, A) o 6! ah oo Q. \J s.\) UE :.: 6= -6v!()\J =sr q)q)(,) c) ;: 0) -O U: o(c .r. 0.) H C6Io1,l :: (JI >dlq/(JI E >.1 <) -ol tY 0)!00tr(!0)t uo l- cB tr(.)oc F63 .9 rhG: 6I v'l CJI -t -ot .cltil €q) c! Iq) 0) Ft q) q) (, 4) U) c) 2.7. Ordering, storage and delivery of ivermectin Mectizan@ ordered/applied for by - Qtlease tick the appropriate answer) MOH tr WHOD I.NICEFN NGDOtr Other (please specify) Mectizan@ delivered by - (please tick the appropriate answer) MoH tr wHotr I.INICEFtr NGDOtr Other (please specify) Please describe how Mectizan@ is ordered and how it gets to the communities Table l0: Mectizan@ lnventory (Please add more rows if necessary) Number of Mectizan tablets NOTE: The project did not request any Mectizan because it had enough for next distribution How are the remaining ivermectin tablets collected and where are they kept? They are collected through the HSAs and are kept in the district pharmacy. List and briefly describe the activities under ivermectin delivery that are being carried out by health care personnel in the project area. From district coordinator to health center to CDDs and through the same channel to the district pharmacist Any other comments 2.8. Gommunity self-monitoring and Stakeholders Meeting Has any training (of trainers) for community self-monitoring been done in the projectarea? If so, When? Table I l: Community self-monitoring and Stakeholders Meeting (Add rows if needed) State/Districti LGA Requested Received Used Lost Wasted Expired Remaining CHIKWAWA 20s,987 205987 I 96887 987 0 0 8l l3 TOTAL t6 WI-lO/APOC. 24 Novembcr 2004 a District/ LGA Total # of communities/villages in the entire project area No of Communities that carried out self monitoring (CSM) No of Communities that conducted stakeholders meeting (SHM) CHIKWAWA 128 0 0 TOTAL Describe how the results of the community self- monitoring and stakeholders meetings have affected project implementation or how they would be utilized during the next treatment cycle. 2.9. Supervision 2.9.1. 2.9.2. 2.9.3. 2.9.4. 2.9.5. Provide a flow chart of supervision hierarchy. What were the main issues identified during supervision? Was a supervision checklist used? What were the outcomes at each level of CDTI implementation supervision? Was feedback given to the person or groups supervised? 2.9.6. How was the feedback used to improve the overall performance of the project? SEGTION 3: Support to GDT! 3.{. Equipment Table 12: Status of equipment (Please add more rows if necessary) Source Type of equipment APOC MOH DISTRICT/ LGA NGDO Others No Condrtron No Condrtron No Condrfion No Condrtron No Condrtron l. Vehicle 0 N/A 7 F 0 0 0 2. Motor cycle(s) 1 F 9 F 0 0 0 3. Computer(s) I F 7 F 0 0 0 4. Printer(s) I F 4 F 0 0 0 5. Photocopier (s) 0 N/A 0 N/A 0 0 0 6. Fax Machine(s) 0 N/A 2 F 0 0 0 7. Others a) b) 17 WHO/APOC. 24 November 2004 \ Ac) *Condition of the equipment (F:Functional, CNFR:Currently non-functional but repairable, WO:Written off). How does the project intend to maintain and replace existing equipment and other materials? 18 WHO/APOC. 24 November 2004 aI ', t I 3.2. Financial contributions of the pailners and communities Table l3: Financial contributions by all partners for the last three years If there are problems with release of counterpart funds, how were they addressed? Additional comments 3.3. Other forms of community support Describe (indicate forms of in-kind contributions of communities if any) 3.4. Expenditure per activity Indicate in table 14, the amount expended during the reporting period for each activity listed. Write the amount expended in US dollars using the current United Nations exchange rate to local currency. Indictate exchange rate used here Contributor Year I ('provde the perrcd') Year 2 ('provde the pernd') Year 3 ('provde the perrcd') TOTA L TOTAL Cash Released (us$) Cash Budgeted (us$) TOTAL Cash Budgeted (us$) TOTAL Cash Released (us$) TOTAL Cash Budgeted (us$) TOTAL Cash Released (us$) MOH (Central + Provincial/State) MOH (District/LGA) LocalNGDO(s) ( if any) I NGDO partner(s) Others a) I I b) Communities APOC Trust Fund TOTAL t9 WHO/APOC, 24 November 2004 Table l4: Indicate how much the project spent for each activity listed below during the reporting period Any comments or explanations? SEGTION 4: Sustainability of GDTI 4.1. lnterna!; independent participatory monitoringl Evaluation 4,1.1 Was Monitoring/evaluation carried out during the reporting period? (tick any of the following which are applicable) Year I Participatory Independent monitoring Mid Term Sustainability Evaluation 5 year Sustainability Evaluation Internal Monitoring by NOTF Other Evaluation by other partners 4.1.2. What were the recommendations? 4.1,3. How have they been implemented? Activify Expenditure ($ US) Source(s) of fundins Drug delivery from NOTF HQ area to central collection point of community Mobilization and health education of communities Training of CDDs Training of health staff at all levels Supervising CDDs and distribution Internal monitoring of CDTI activities Advocacy visits to health and politicaI authorities IEC materials Summary (reporting) forms for treatment Vehicles/ Motorcycles/ bicycles maintenance Office Equipment (e.g compr-rters, printers etc) Others TOTAL Total number of ns treated 20 WHO/APOC. 24 November 2004 .a l1 ' , ,l I\l , i t,1r' I 4.2. Sustainability of projects: plan and set targets (mandatory at Yr 3) Was the project evaluated during the reporting period?_ Was a sustainability plan written?_ When was the sustainability plan submitted?_ What arrangements have been made to sustain CDTI after APOC funding ceases in terms of: 4.2.1. Planning at all relevant levels 4.2.2. Funds 4.2.3 Transport(replacementandmaintenance) 4.2.4. Other resources 4.2.5. To what extent has the plan been implemented 4.3. Integration Outline the extent of integration of CDTI into the PHC structure and the plans for complete integration: 4.3.1. Ivermectin delivery mechanisms Training Joint supervision and monitoring with other programs Release of funds for project activities Is CDTI included in the PHC budgetr Describe other health programmes that are using the cDTI structure and how this was achieved. What have been the achievements? Describe others issues considered in the integration of CDTI. 4.3.2. 4.3.3. 4.3.4. 4.4. Operational research 4.3.5. 4.3.6. 4.3.7. 4.4.1. 4.4.2. summarize in not more than one half of a page the operationar research undertaken in the project area within the reporting period. How were the results applied in the project? 21 WIIO/APOC. 24 November 2004 ' 't,1 tJ' SECTION 5: Strengths, weaknesses, challengcsr and opportunities List the strengths and weaknesses of CDTI implementation process List the challenges and indicate how they were addressed. SEGTION 6: matters Unique features of the proiecUother 22 WHO/APOC. 24 November 2004